Xiaobo Yang
机构：Guangzhou University of Chinese Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital · ORCID：0000-0003-1929-8866
发表论文 137 篇 · 总被引 4507 次 · h-index 38
代表论文
- Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma (2024 · Journal for ImmunoTherapy of Cancer · 被引 45)
- Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial (2024 · BMC Medicine · 被引 33)
- Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis (2023 · Cancer Immunology Immunotherapy · 被引 25)
- Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study (2024 · International Journal of Surgery · 被引 21)
- Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study (2023 · The Oncologist · 被引 14)
- Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer (2024 · International Immunopharmacology · 被引 13)